[AvocadoPanic]

The 'risk' here is often carried by publicly funded research. ~6.2 billion for glp

The private 'investment' comes in manufacturing, scale and marketing.

Novo Nordisk has spent 41% more on shareholder enrichment (buybacks and dividends) than on R&D over the past five years.

[15155]

> Novo Nordisk has spent 41% more on shareholder enrichment (buybacks and dividends) than on R&D over the past five years.

So they are good stewards of their funds and know they can't deploy as much as they have? Berkshire Hathaway does the same thing.

[AvocadoPanic]

Is Berkshire Hathaway able to monitize the output of government funded research as effectively?